Literature DB >> 12794051

Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis.

M Cutolo1, A Sulli, C Pizzorni, C Craviotto, R H Straub.   

Abstract

Rheumatoid arthritis (RA) as well as most autoimmune disorders results from a combination of several predisposing factors including the relations between epitopes of the trigger agent (i.e., virus, self-antigens) and histocompatibility epitopes (i.e., HLA), the status of the stress response system including the hypothalamic-pituitary-adrenocortical axis (HPA) and the sympathetic nervous system (SNS), as well as the gonadal hormones (hypothalamic-pituitary-gonadal axis, HPG), with estrogens implicated as enhancers of the immune response and androgens and progesterone as natural suppressors. The regular observation of reduced cortisol and adrenal androgen secretion during testing in RA patients not treated with glucocorticoids should clearly be regarded as "relative adrenal insufficiency" in the setting of a sustained inflammatory process, as shown by high interleukin (IL)-6 levels. In polymyalgia rheumatica, several pathogenetic and clinical aspects of the disease might well overlap RA, at least with elderly onset RA (EORA). Therefore, reduced production of adrenal hormones (i.e., cortisol, DHEAS) at baseline in active and untreated patients with polymyalgia rheumatica was detected. The defect was mainly related to altered adrenal responsiveness to ACTH stimulation (i.e., increased 17-OHP), at least in untreated patients with polymyalgia rheumatica. Finally, normal serum estrogen and low androgen levels, but high synovial fluid estrogen and much lower androgen levels, have been found in RA patients, supporting the fundamental role of the peripheral sex hormone metabolism in the manifestations of the disease.

Entities:  

Mesh:

Year:  2003        PMID: 12794051     DOI: 10.1111/j.1749-6632.2003.tb03142.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  14 in total

1.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

Review 2.  Psychoneuroimmunology-developments in stress research.

Authors:  Rainer H Straub; Maurizio Cutolo
Journal:  Wien Med Wochenschr       Date:  2017-06-09

3.  Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.

Authors:  M Cutolo; C M Montecucco; L Cavagna; R Caporali; S Capellino; P Montagna; L Fazzuoli; B Villaggio; B Seriolo; A Sulli
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

Review 4.  Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research.

Authors:  Kristen Davies; Emma Dures; Wan-Fai Ng
Journal:  Nat Rev Rheumatol       Date:  2021-10-01       Impact factor: 20.543

Review 5.  Stress and reproductive failure: past notions, present insights and future directions.

Authors:  Katrina Nakamura; Sam Sheps; Petra Clara Arck
Journal:  J Assist Reprod Genet       Date:  2008-02-15       Impact factor: 3.412

6.  Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.

Authors:  S Guiducci; A Del Rosso; M Cinelli; F Perfetto; R Livi; A Rossi; A Gabrielli; R Giacomelli; N Iori; G Fibbi; M Del Rosso; M Matucci Cerinic
Journal:  Arthritis Res Ther       Date:  2005-09-08       Impact factor: 5.156

Review 7.  The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.

Authors:  Maurizio Cutolo; Cornelia M Spies; Frank Buttgereit; Sabrina Paolino; Carmen Pizzorni
Journal:  Arthritis Res Ther       Date:  2014-11-13       Impact factor: 5.156

8.  Enhanced reactivity to pain in patients with rheumatoid arthritis.

Authors:  Robert R Edwards; Ajay D Wasan; Clifton O Bingham; Joan Bathon; Jennifer A Haythornthwaite; Michael T Smith; Gayle G Page
Journal:  Arthritis Res Ther       Date:  2009-05-04       Impact factor: 5.156

9.  Early menopause and severity of rheumatoid arthritis in women older than 45 years.

Authors:  Mitra Pikwer; Jan-Åke Nilsson; Ulf Bergström; Lennart T H Jacobsson; Carl Turesson
Journal:  Arthritis Res Ther       Date:  2012-08-17       Impact factor: 5.156

10.  Diurnal secretion of growth hormone, cortisol, and dehydroepiandrosterone in pre- and perimenopausal women with active rheumatoid arthritis: a pilot case-control study.

Authors:  Marc R Blackman; Ranganath Muniyappa; Mildred Wilson; Barbara E Moquin; Howard L Baldwin; Kelli A Wong; Christopher Snyder; Michael Magalnick; Shaan Alli; James Reynolds; Seth M Steinberg; Raphaela Goldbach-Mansky
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.